602 related articles for article (PubMed ID: 34804061)
1. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
Fei L; Ren X; Yu H; Zhan Y
Front Immunol; 2021; 12():771210. PubMed ID: 34804061
[TBL] [Abstract][Full Text] [Related]
2. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.
Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B
J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489
[TBL] [Abstract][Full Text] [Related]
3. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
4. CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments.
Brummer G; Fang W; Smart C; Zinda B; Alissa N; Berkland C; Miller D; Cheng N
Oncogene; 2020 Mar; 39(11):2275-2289. PubMed ID: 31827233
[TBL] [Abstract][Full Text] [Related]
5. CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated with TNFα-Mediated Resistance.
Mondini M; Loyher PL; Hamon P; Gerbé de Thoré M; Laviron M; Berthelot K; Clémenson C; Salomon BL; Combadière C; Deutsch E; Boissonnas A
Cancer Immunol Res; 2019 Mar; 7(3):376-387. PubMed ID: 30696630
[TBL] [Abstract][Full Text] [Related]
6. Roles of CCL2-CCR2 Axis in the Tumor Microenvironment.
Kadomoto S; Izumi K; Mizokami A
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445235
[TBL] [Abstract][Full Text] [Related]
7. Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy.
Ben-Yehuda H; Arad M; Peralta Ramos JM; Sharon E; Castellani G; Ferrera S; Cahalon L; Colaiuta SP; Salame TM; Schwartz M
Mol Neurodegener; 2021 Jun; 16(1):39. PubMed ID: 34172073
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.
Sanford DE; Belt BA; Panni RZ; Mayer A; Deshpande AD; Carpenter D; Mitchem JB; Plambeck-Suess SM; Worley LA; Goetz BD; Wang-Gillam A; Eberlein TJ; Denardo DG; Goedegebuure SP; Linehan DC
Clin Cancer Res; 2013 Jul; 19(13):3404-15. PubMed ID: 23653148
[TBL] [Abstract][Full Text] [Related]
9. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2
Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK
Front Immunol; 2022; 13():993444. PubMed ID: 36685592
[TBL] [Abstract][Full Text] [Related]
10. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.
Huang B; Lei Z; Zhao J; Gong W; Liu J; Chen Z; Liu Y; Li D; Yuan Y; Zhang GM; Feng ZH
Cancer Lett; 2007 Jul; 252(1):86-92. PubMed ID: 17257744
[TBL] [Abstract][Full Text] [Related]
11. Recruitment of γδ T cells to the lesion via the CCL2/CCR2 signaling after spinal cord injury.
Xu P; Zhang F; Chang MM; Zhong C; Sun CH; Zhu HR; Yao JC; Li ZZ; Li ST; Zhang WC; Sun GD
J Neuroinflammation; 2021 Mar; 18(1):64. PubMed ID: 33653377
[TBL] [Abstract][Full Text] [Related]
12. Role of CCL2/CCR2 axis in the immunopathogenesis of rheumatoid arthritis: Latest evidence and therapeutic approaches.
Moadab F; Khorramdelazad H; Abbasifard M
Life Sci; 2021 Mar; 269():119034. PubMed ID: 33453247
[TBL] [Abstract][Full Text] [Related]
13. Myeloid NEMO deficiency promotes tumor immunosuppression partly via MCP1-CCR2 axis.
Yuanyuan L; Yakun L; Zhongyao L; Le Y; Weisong D; Moran G; Hui B; Chunyan L
Exp Cell Res; 2021 Feb; 399(2):112467. PubMed ID: 33428904
[TBL] [Abstract][Full Text] [Related]
14. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
15. Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?
Iwamoto H; Izumi K; Mizokami A
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297571
[TBL] [Abstract][Full Text] [Related]
16. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract][Full Text] [Related]
17. Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting.
Xu M; Wang Y; Xia R; Wei Y; Wei X
Cell Prolif; 2021 Oct; 54(10):e13115. PubMed ID: 34464477
[TBL] [Abstract][Full Text] [Related]
18. Monocytic myeloid-derived suppressor cells home to tumor-draining lymph nodes via CCR2 and locally modulate the immune response.
Lahmar Q; Schouppe E; Morias Y; Van Overmeire E; De Baetselier P; Movahedi K; Laoui D; Sarukhan A; Van Ginderachter JA
Cell Immunol; 2021 Apr; 362():104296. PubMed ID: 33556903
[TBL] [Abstract][Full Text] [Related]
19. CCL3/CCR1 mediates CD14
Zhao X; Gu M; Xu X; Wen X; Yang G; Li L; Sheng P; Meng F
Osteoarthritis Cartilage; 2020 May; 28(5):613-625. PubMed ID: 32006659
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis.
Izhak L; Wildbaum G; Jung S; Stein A; Shaked Y; Karin N
PLoS One; 2012; 7(1):e28305. PubMed ID: 22279523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
